Preclinical Validation of [177Lu]Lu-AKIR001, a CD44v6-Targeted Radiotherapeutic Entering First-in-Human Trials.
Anja C L Mortensen, Tabassom Mohajershojai, Amanda Gustafsson...
https://pubmed.ncbi.nlm.nih.gov/41198237/Actively Recruiting
Early Phase 1
Age: 18Years +
All Genders
ID06639191
Phase 1 Study of 177LuLu-AKIR001 to Assess Safety and Anti-Tumor Effects in Adults with Advanced CD44v6-Positive Solid Tumors
Led by Karolinska University Hospital · Updated on 2026-01-30
15
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the safety and tolerability of increasing doses of 177LuLu-AKIR001, a drug targeting CD44v6-expressing solid tumors that cannot be surgically removed or have spread. This early phase 1 trial focuses on patients with advanced cancers such as thyroid gland anaplastic carcinoma, poorly differentiated thyroid carcinoma, head and neck cancer, cervix carcinoma, vulvar cancer stage IV, and non-small cell lung cancer stage IV, who have no other reasonable treatment options. The main goal is to understand the toxicity profile of 177LuLu-AKIR001 by monitoring dose-limiting toxicities and serious adverse events.
CONDITIONS
Brief Title
[177Lu]Lu-AKIR001 First-in-human Study
Research Team
R
Renske Altena, Associate Professor, MD PhD
T
Thuy Tran, Associate Prof, PharmD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here